Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DDMAC's Expanding Catalog Of Studies

You may also be interested in...

Census Delays Planned DDMAC Studies On Various Aspects Of DTC Advertising

FDA's ability to conduct studies of direct-to-consumer advertising is being impacted by the 2010 census, slowing two pending FDA studies just as the agency is preparing to start three more

“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study

FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions

FDA Advertising Oversight Will Consider Impact Of “Puppies” And The Internet

FDA is pushing forward several research initiatives to help better define how print and broadcast direct-to-consumer ads should be structured, but the agency is adopting a less formal approach to oversight of Internet advertising


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts